Positive News SentimentPositive NewsNYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis $13.04 +0.32 (+2.48%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Zymeworks Stock (NYSE:ZYME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zymeworks alerts:Sign Up Key Stats Today's Range$12.80▼$13.2150-Day Range$11.10▼$15.0152-Week Range$7.97▼$17.70Volume184,442 shsAverage Volume474,780 shsMarket Capitalization$906.94 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingModerate Buy Company OverviewZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More… Remove Ads Zymeworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreZYME MarketRank™: Zymeworks scored higher than 54% of companies evaluated by MarketBeat, and ranked 473rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 3 research reports in the past 90 days.Read more about Zymeworks' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zymeworks are expected to decrease in the coming year, from ($1.39) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zymeworks' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ZYME. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ZYME. News and Social Media3.7 / 5News Sentiment1.61 News SentimentZymeworks has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Zymeworks this week, compared to 4 articles on an average week.Search Interest2 people have searched for ZYME on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have bought 1,346.67% more of their company's stock than they have sold. Specifically, they have bought $19,339,774.00 in company stock and sold $1,336,847.00 in company stock.Percentage Held by InsidersOnly 1.92% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Stock News HeadlinesZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 56,277 SharesMarch 20, 2025 | insidertrades.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 320,690 Shares of StockMarch 14, 2025 | insidertrades.com Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!March 24, 2025 | Paradigm Press (Ad)Insiders Are Spending Big: 15 Stocks Leading in MarchMarch 22 at 6:19 AM | insidermonkey.comLifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)March 15, 2025 | markets.businessinsider.comHuge Insider Buying: Victoria's Secret, Carl Icahn, and MoreMarch 15, 2025 | 247wallst.comZymeworks (ZYME) Shares Surge Amid Positive Analyst ForecastsMarch 12, 2025 | markets.businessinsider.comZymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?March 12, 2025 | msn.comSee More Headlines ZYME Stock Analysis - Frequently Asked Questions How have ZYME shares performed this year? Zymeworks' stock was trading at $14.64 on January 1st, 2025. Since then, ZYME shares have decreased by 10.3% and is now trading at $13.13. View the best growth stocks for 2025 here. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Thursday, October, 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. The firm's revenue was down 3.1% on a year-over-year basis. When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' top institutional investors include Redmile Group LLC (7.03%), BVF Inc. IL (6.26%), Vanguard Group Inc. (3.62%) and Deutsche Bank AG (2.25%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Paul Andrew Moore, Neil Josephson, Jeffrey T L Smith and Christopher Astle. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings10/31/2024Today3/24/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$30.00 Low Stock Price Target$13.00 Potential Upside/Downside+65.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-182.75% Pretax Margin-189.75% Return on Equity-23.00% Return on Assets-18.04% Debt Debt-to-Equity RatioN/A Current Ratio4.10 Quick Ratio4.10 Sales & Book Value Annual Sales$76.30 million Price / Sales11.60 Cash FlowN/A Price / Cash FlowN/A Book Value$6.63 per share Price / Book1.92Miscellaneous Outstanding Shares69,577,000Free Float67,556,000Market Cap$885.02 million OptionableOptionable Beta1.13 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NYSE:ZYME) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.